Multiple Sclerosis News Today | Symptoms, Diagnosis, Treatments
2024年12月4日 · Get the latest multiple sclerosis news, patient views, and caregiver perspectives from one of the largest MS communities online. ... December 5, 2024 News by Marisa Wexler, MS.
Top 10 MS stories of 2023 - Multiple Sclerosis News Today
News; Top 10 MS stories of 2023 Top 10 MS stories of 2023. Of most interest to readers was news on potential treatments, triggers. by Marisa Wexler, MS | January 2, 2024.
The MS News Today Podcast - Multiple Sclerosis News Today
After 24 years with the National MS Society, most recently as Chief Advocacy, Services and Science Officer, Dr. Tim Coetzee is the new President and CEO of the Society.
1-year fenebrutinib inhibits nearly all MS signs in relapsing MS trial
2024年9月6日 · The Phase 2 FENopta trial (NCT05119569) evaluated fenebrutinib’s safety and efficacy in 109 adults, ages 18-55, with relapsing forms of MS, including relapsing-remitting MS and active secondary ...
MRI analysis of MS ReBUILD data shows remyelination with...
2023年6月16日 · October 8, 2024 News by Esteban Domínguez Cerezo, MS. Nerve stimulator for myelin repair to enter RRMS clinical trial. March 6, 2024 News by Marisa Wexler, MS.
MS news notes: Vaccines, migraines, eye-tracking technology
2023年9月18日 · The MS News Today story “No greater risk of hospitalization found after vaccines in MS in study” reports on a nationwide study in France involving over 100,000 people, that “found no ...
MS news notes: Stem cell therapy, early Aubagio use, DMTs
2023年5月1日 · Stem cell therapy receives a good report card. The MS News Today article “AAN 2023: Low rates of disease activity after stem cell transplant” reports on a follow-up study of 22 autologous ...
MS news notes: Vumerity, herpes virus, caregivers
2023年11月27日 · Final results are in from the EVOLVE-MS-1 clinical trial for patients with relapsing-remitting MS (RRMS) who were treated with Vumerity (diroximel fumarate), and the news is quite positive, as MS ...
MS news notes: Stem cell therapy, genetic variant, diet
2023年7月3日 · The MS News Today article “Stem cell therapy highly effective in active RRMS: Real-world study” reports that nearly 80% of participants with highly active relapsing-remitting multiple ...
FDA OKs Phase 2 clinical trial of KYV-101 for progressive MS
2024年1月5日 · November 7, 2024 News by Marisa Wexler, MS. Hope Biosciences’ stem cell therapy shows promise in small Phase 2 trial. October 15, 2024 News by Lindsey Shapiro, PhD.